Why no Bad-Ad Program letters?

Share this article:

OPDP's Bad Ad Program, which launched in May 2010, was meant to help physicians spot misleading drug promotion and offer an easy way to report the activity. But four years on, some question its impact.

While two dozen enforcement letters were sent by FDA's Office of Prescription Drug Promotion to pharma companies last year, up from 21 in 2012, none of the letters were prompted by the Bad Ad Program.

“Have healthcare providers stopped reporting misleading activities to the FDA, or is there another explanation for the decline?” asks Porzio LifeSciences's Kim Capone, a senior regulatory analyst who tabulated the figures, in an April note to the advisory firm's clients.

According to Capone, Bad Ad Program letters peaked in 2011 with five, falling to three in 2012 and none in 2013. Enforcement is but one component of OPDP oversight of prescription drug promotion, an FDA press officer told MM&M. “Therefore, one cannot get a complete picture of OPDP's program area by looking at a snapshot of time for enforcement letters.” Capone was not available at press time.

To raise awareness of the program, the FDA last year launched an e-learning CME/CE course to help HCPs and med students learn to identify prescription drug promotion that may be misleading or raise other regulatory issues and report it, offering several case studies based on enforcement letters.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?